GREY:IPHAF - Post by User
Post by
antoninuson Apr 26, 2010 12:18pm
437 Views
Post# 17031229
certican
certicanis already marketed in over 70 countries.
this is NOT a competitor to 247
having said that, certican(zortress) does enable lower levels of cyclosporin in the combination regimen, therefore possibly reducing side effects, so in a way, it could impact sales. I am guessing that certican in combo with voclo will be far more effective that certican with cyclo. It is possible that zortress(certican) will help isotechnika not hurt it.
by the way isaloser, you seem to ONLY write negatively...why is that? while I have had my fair share of objections, I still believe in the drug and think we are well positioned for the next few years...there is NOTHING to suggest that palladin is uninvolved...they are actually quite involved ...why else would their CEO own so many shares if he didnt believe in the companies prospects?
regardless, Isa needs a tx PARTNER.
Psoriasis is I believe dead...we way overpsent for that indication which will simply not come to fruition. I THINK isa unecessarily blew approx $200 million on psoriasis development when the market was just too fragmented and too small. That said, we need TX and we need lux to really dominate the market.